Eltrombopag  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
chronic  ||| S:33 E:41 ||| JJ
idiopathic  ||| S:41 E:52 ||| NNS
( ||| S:52 E:53 ||| -LRB-
immune ||| S:53 E:59 ||| JJ
)  ||| S:59 E:61 ||| -RRB-
thrombocytopenic  ||| S:61 E:78 ||| FW
purpura  ||| S:78 E:86 ||| FW
( ||| S:86 E:87 ||| -LRB-
ITP ||| S:87 E:90 ||| NNP
)  ||| S:90 E:92 ||| -RRB-
This  ||| S:92 E:97 ||| DT
paper  ||| S:97 E:103 ||| NN
presents  ||| S:103 E:112 ||| VBZ
a  ||| S:112 E:114 ||| DT
summary  ||| S:114 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
the  ||| S:125 E:129 ||| DT
evidence  ||| S:129 E:138 ||| NN
review  ||| S:138 E:145 ||| NN
group  ||| S:145 E:151 ||| NN
( ||| S:151 E:152 ||| -LRB-
ERG ||| S:152 E:155 ||| NNP
)  ||| S:155 E:157 ||| -RRB-
report  ||| S:157 E:164 ||| NN
into  ||| S:164 E:169 ||| IN
the  ||| S:169 E:173 ||| DT
clinical  ||| S:173 E:182 ||| JJ
effectiveness  ||| S:182 E:196 ||| NN
and  ||| S:196 E:200 ||| CC
cost-effectiveness  ||| S:200 E:219 ||| JJ
of  ||| S:219 E:222 ||| IN
eltrombopag  ||| S:222 E:234 ||| NN
for  ||| S:234 E:238 ||| IN
the  ||| S:238 E:242 ||| DT
treatment  ||| S:242 E:252 ||| NN
of  ||| S:252 E:255 ||| IN
adults  ||| S:255 E:262 ||| NNS
with  ||| S:262 E:267 ||| IN
chronic  ||| S:267 E:275 ||| JJ
idiopathic  ||| S:275 E:286 ||| NNS
( ||| S:286 E:287 ||| -LRB-
immune ||| S:287 E:293 ||| JJ
)  ||| S:293 E:295 ||| -RRB-
thrombocytopenic  ||| S:295 E:312 ||| FW
purpura  ||| S:312 E:320 ||| FW
( ||| S:320 E:321 ||| -LRB-
ITP ||| S:321 E:324 ||| NNP
) ||| S:324 E:325 ||| -RRB-
,  ||| S:325 E:327 ||| ,
based  ||| S:327 E:333 ||| VBN
on  ||| S:333 E:336 ||| IN
a  ||| S:336 E:338 ||| DT
review  ||| S:338 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
the  ||| S:348 E:352 ||| DT
manufacturer ||| S:352 E:364 ||| NN
's  ||| S:364 E:367 ||| POS
submission  ||| S:367 E:378 ||| NN
( ||| S:378 E:379 ||| -LRB-
MS ||| S:379 E:381 ||| NNP
)  ||| S:381 E:383 ||| -RRB-
to  ||| S:383 E:386 ||| TO
the  ||| S:386 E:390 ||| DT
National  ||| S:390 E:399 ||| NNP
Institute  ||| S:399 E:409 ||| NNP
for  ||| S:409 E:413 ||| IN
Health  ||| S:413 E:420 ||| NNP
and  ||| S:420 E:424 ||| CC
Clinical  ||| S:424 E:433 ||| NNP
Excellence  ||| S:433 E:444 ||| NNP
( ||| S:444 E:445 ||| -LRB-
NICE ||| S:445 E:449 ||| NNP
)  ||| S:449 E:451 ||| -RRB-
as  ||| S:451 E:454 ||| IN
part  ||| S:454 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
the  ||| S:462 E:466 ||| DT
single  ||| S:466 E:473 ||| JJ
technology  ||| S:473 E:484 ||| NN
appraisal  ||| S:484 E:494 ||| NN
process ||| S:494 E:501 ||| NN
.  ||| S:501 E:503 ||| .
ITP  ||| S:503 E:507 ||| NNP
is  ||| S:507 E:510 ||| VBZ
an  ||| S:510 E:513 ||| DT
autoimmune  ||| S:513 E:524 ||| JJ
disorder  ||| S:524 E:533 ||| NN
by  ||| S:533 E:536 ||| IN
which  ||| S:536 E:542 ||| WDT
antibodies  ||| S:542 E:553 ||| NNS
are  ||| S:553 E:557 ||| VBP
formed  ||| S:557 E:564 ||| VBN
against  ||| S:564 E:572 ||| IN
platelets  ||| S:572 E:582 ||| NN
with  ||| S:582 E:587 ||| IN
annual  ||| S:587 E:594 ||| JJ
incidence  ||| S:594 E:604 ||| NN
rates  ||| S:604 E:610 ||| NNS
in  ||| S:610 E:613 ||| IN
the  ||| S:613 E:617 ||| DT
UK ||| S:617 E:619 ||| NNP
/ ||| S:619 E:620 ||| NNP
USA  ||| S:620 E:624 ||| NNP
ranging  ||| S:624 E:632 ||| VBG
from  ||| S:632 E:637 ||| IN
1.13  ||| S:637 E:642 ||| CD
to  ||| S:642 E:645 ||| TO
6.62  ||| S:645 E:650 ||| CD
cases  ||| S:650 E:656 ||| NNS
per  ||| S:656 E:660 ||| IN
100,000  ||| S:660 E:668 ||| CD
adults ||| S:668 E:674 ||| NNS
.  ||| S:674 E:676 ||| .
Eltrombopag  ||| S:676 E:688 ||| NNP
increases  ||| S:688 E:698 ||| VBZ
the  ||| S:698 E:702 ||| DT
production  ||| S:702 E:713 ||| NN
of  ||| S:713 E:716 ||| IN
platelets  ||| S:716 E:726 ||| NN
at  ||| S:726 E:729 ||| IN
a  ||| S:729 E:731 ||| DT
rate  ||| S:731 E:736 ||| NN
that  ||| S:736 E:741 ||| IN
outpaces  ||| S:741 E:750 ||| VBG
their  ||| S:750 E:756 ||| PRP$
destruction  ||| S:756 E:768 ||| NN
by  ||| S:768 E:771 ||| IN
the  ||| S:771 E:775 ||| DT
immune  ||| S:775 E:782 ||| JJ
system ||| S:782 E:788 ||| NN
,  ||| S:788 E:790 ||| ,
and  ||| S:790 E:794 ||| CC
has  ||| S:794 E:798 ||| VBZ
a  ||| S:798 E:800 ||| DT
UK  ||| S:800 E:803 ||| NNP
marketing  ||| S:803 E:813 ||| NN
authorisation  ||| S:813 E:827 ||| NNS
both  ||| S:827 E:832 ||| CC
for  ||| S:832 E:836 ||| IN
the  ||| S:836 E:840 ||| DT
treatment  ||| S:840 E:850 ||| NN
of  ||| S:850 E:853 ||| IN
adult  ||| S:853 E:859 ||| NN
ITP  ||| S:859 E:863 ||| NN
in  ||| S:863 E:866 ||| IN
splenectomised  ||| S:866 E:881 ||| JJ
patients  ||| S:881 E:890 ||| NNS
who  ||| S:890 E:894 ||| WP
are  ||| S:894 E:898 ||| VBP
refractory  ||| S:898 E:909 ||| VBN
to  ||| S:909 E:912 ||| TO
other  ||| S:912 E:918 ||| JJ
treatments  ||| S:918 E:929 ||| NNS
and  ||| S:929 E:933 ||| CC
as  ||| S:933 E:936 ||| IN
a  ||| S:936 E:938 ||| DT
second-line  ||| S:938 E:950 ||| JJ
treatment  ||| S:950 E:960 ||| NN
for  ||| S:960 E:964 ||| IN
adult  ||| S:964 E:970 ||| JJ
non-splenectomised  ||| S:970 E:989 ||| JJ
patients  ||| S:989 E:998 ||| NNS
for  ||| S:998 E:1002 ||| IN
whom  ||| S:1002 E:1007 ||| WP
surgery  ||| S:1007 E:1015 ||| NN
is  ||| S:1015 E:1018 ||| VBZ
contraindicated ||| S:1018 E:1033 ||| VBN
.  ||| S:1033 E:1035 ||| .
Both  ||| S:1035 E:1040 ||| DT
splenectomised  ||| S:1040 E:1055 ||| NN
and  ||| S:1055 E:1059 ||| CC
non-splenectomised  ||| S:1059 E:1078 ||| JJ
patient  ||| S:1078 E:1086 ||| NN
groups  ||| S:1086 E:1093 ||| NNS
were  ||| S:1093 E:1098 ||| VBD
considered  ||| S:1098 E:1109 ||| VBN
in  ||| S:1109 E:1112 ||| IN
the  ||| S:1112 E:1116 ||| DT
analysis ||| S:1116 E:1124 ||| NN
.  ||| S:1124 E:1126 ||| .
Two  ||| S:1126 E:1130 ||| CD
economic  ||| S:1130 E:1139 ||| JJ
models  ||| S:1139 E:1146 ||| NNS
were  ||| S:1146 E:1151 ||| VBD
presented ||| S:1151 E:1160 ||| VBN
,  ||| S:1160 E:1162 ||| ,
one  ||| S:1162 E:1166 ||| CD
for  ||| S:1166 E:1170 ||| IN
a  ||| S:1170 E:1172 ||| DT
watch-and-rescue  ||| S:1172 E:1189 ||| JJ
treatment  ||| S:1189 E:1199 ||| NN
scenario  ||| S:1199 E:1208 ||| NN
and  ||| S:1208 E:1212 ||| CC
the  ||| S:1212 E:1216 ||| DT
second  ||| S:1216 E:1223 ||| JJ
for  ||| S:1223 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
long-term  ||| S:1231 E:1241 ||| JJ
treatment  ||| S:1241 E:1251 ||| NN
of  ||| S:1251 E:1254 ||| IN
patients  ||| S:1254 E:1263 ||| NNS
with  ||| S:1263 E:1268 ||| IN
more  ||| S:1268 E:1273 ||| RBR
severe  ||| S:1273 E:1280 ||| JJ
ITP ||| S:1280 E:1283 ||| NNP
.  ||| S:1283 E:1285 ||| .
The  ||| S:1285 E:1289 ||| DT
submission ||| S:1289 E:1299 ||| NN
's  ||| S:1299 E:1302 ||| POS
evidence  ||| S:1302 E:1311 ||| NN
was  ||| S:1311 E:1315 ||| VBD
sourced  ||| S:1315 E:1323 ||| VBN
from  ||| S:1323 E:1328 ||| IN
the  ||| S:1328 E:1332 ||| DT
relatively  ||| S:1332 E:1343 ||| RB
high-quality  ||| S:1343 E:1356 ||| JJ
RAISE  ||| S:1356 E:1362 ||| NNP
[ ||| S:1362 E:1363 ||| -LRB-
RAndomized  ||| S:1363 E:1374 ||| FW
placebo-controlled  ||| S:1374 E:1393 ||| FW
Idiopathic  ||| S:1393 E:1404 ||| FW
thrombocytopenic  ||| S:1404 E:1421 ||| FW
purpura  ||| S:1421 E:1429 ||| FW
( ||| S:1429 E:1430 ||| -LRB-
ITP ||| S:1430 E:1433 ||| NNP
)  ||| S:1433 E:1435 ||| -RRB-
Study  ||| S:1435 E:1441 ||| NN
with  ||| S:1441 E:1446 ||| IN
Eltrombopag ||| S:1446 E:1457 ||| NNP
]  ||| S:1457 E:1459 ||| -RRB-
randomised  ||| S:1459 E:1470 ||| VBZ
controlled  ||| S:1470 E:1481 ||| VBN
trial ||| S:1481 E:1486 ||| NN
.  ||| S:1486 E:1488 ||| .
The  ||| S:1488 E:1492 ||| DT
study  ||| S:1492 E:1498 ||| NN
indicated  ||| S:1498 E:1508 ||| VBD
a  ||| S:1508 E:1510 ||| DT
statistically  ||| S:1510 E:1524 ||| JJ
significant  ||| S:1524 E:1536 ||| JJ
difference  ||| S:1536 E:1547 ||| NN
in  ||| S:1547 E:1550 ||| IN
favour  ||| S:1550 E:1557 ||| NN
of  ||| S:1557 E:1560 ||| IN
eltrombopag  ||| S:1560 E:1572 ||| VBG
compared  ||| S:1572 E:1581 ||| VBN
with  ||| S:1581 E:1586 ||| IN
placebo  ||| S:1586 E:1594 ||| NN
in  ||| S:1594 E:1597 ||| IN
the  ||| S:1597 E:1601 ||| DT
odds  ||| S:1601 E:1606 ||| NNS
of  ||| S:1606 E:1609 ||| IN
achieving  ||| S:1609 E:1619 ||| VBG
the  ||| S:1619 E:1623 ||| DT
primary  ||| S:1623 E:1631 ||| JJ
outcome  ||| S:1631 E:1639 ||| NN
of  ||| S:1639 E:1642 ||| IN
a  ||| S:1642 E:1644 ||| DT
platelet  ||| S:1644 E:1653 ||| JJ
count  ||| S:1653 E:1659 ||| NN
of  ||| S:1659 E:1662 ||| IN
between  ||| S:1662 E:1670 ||| IN
50  ||| S:1670 E:1673 ||| CD
and  ||| S:1673 E:1677 ||| CC
400  ||| S:1677 E:1681 ||| CD
Ã—  ||| S:1681 E:1683 ||| CD
109 ||| S:1683 E:1686 ||| CD
/ ||| S:1686 E:1687 ||| CD
l  ||| S:1687 E:1689 ||| NN
during  ||| S:1689 E:1696 ||| IN
the  ||| S:1696 E:1700 ||| DT
6-month  ||| S:1700 E:1708 ||| JJ
treatment  ||| S:1708 E:1718 ||| NN
period  ||| S:1718 E:1725 ||| NN
( ||| S:1725 E:1726 ||| -LRB-
odds  ||| S:1726 E:1731 ||| JJ
ratio  ||| S:1731 E:1737 ||| NN
8.2 ||| S:1737 E:1740 ||| CD
,  ||| S:1740 E:1742 ||| ,
99 ||| S:1742 E:1744 ||| CD
%  ||| S:1744 E:1746 ||| NN
confidence  ||| S:1746 E:1757 ||| NN
interval  ||| S:1757 E:1766 ||| VBD
3.6  ||| S:1766 E:1770 ||| CD
to  ||| S:1770 E:1773 ||| TO
18.7 ||| S:1773 E:1777 ||| CD
) ||| S:1777 E:1778 ||| -RRB-
.  ||| S:1778 E:1780 ||| .
In  ||| S:1780 E:1783 ||| IN
the  ||| S:1783 E:1787 ||| DT
eltrombopag  ||| S:1787 E:1799 ||| JJ
group ||| S:1799 E:1804 ||| NN
,  ||| S:1804 E:1806 ||| ,
50 ||| S:1806 E:1808 ||| CD
/ ||| S:1808 E:1809 ||| CD
83  ||| S:1809 E:1812 ||| CD
( ||| S:1812 E:1813 ||| -LRB-
60 ||| S:1813 E:1815 ||| CD
% ||| S:1815 E:1816 ||| NN
)  ||| S:1816 E:1818 ||| -RRB-
non-splenectomised  ||| S:1818 E:1837 ||| JJ
patients  ||| S:1837 E:1846 ||| NNS
and  ||| S:1846 E:1850 ||| CC
18 ||| S:1850 E:1852 ||| CD
/ ||| S:1852 E:1853 ||| CD
49  ||| S:1853 E:1856 ||| CD
( ||| S:1856 E:1857 ||| -LRB-
37 ||| S:1857 E:1859 ||| CD
% ||| S:1859 E:1860 ||| NN
)  ||| S:1860 E:1862 ||| -RRB-
splenectomised  ||| S:1862 E:1877 ||| JJ
patients  ||| S:1877 E:1886 ||| NNS
achieved  ||| S:1886 E:1895 ||| VBD
this  ||| S:1895 E:1900 ||| DT
outcome ||| S:1900 E:1907 ||| NN
.  ||| S:1907 E:1909 ||| .
Median  ||| S:1909 E:1916 ||| JJ
duration  ||| S:1916 E:1925 ||| NN
of  ||| S:1925 E:1928 ||| IN
response  ||| S:1928 E:1937 ||| NN
for  ||| S:1937 E:1941 ||| IN
all  ||| S:1941 E:1945 ||| DT
patients  ||| S:1945 E:1954 ||| NNS
was  ||| S:1954 E:1958 ||| VBD
10.9  ||| S:1958 E:1963 ||| CD
weeks  ||| S:1963 E:1969 ||| NNS
( ||| S:1969 E:1970 ||| -LRB-
splenectomised  ||| S:1970 E:1985 ||| JJ
patients  ||| S:1985 E:1994 ||| NNS
6  ||| S:1994 E:1996 ||| CD
weeks  ||| S:1996 E:2002 ||| NNS
and  ||| S:2002 E:2006 ||| CC
non-splenectomised  ||| S:2006 E:2025 ||| JJ
patients  ||| S:2025 E:2034 ||| NNS
13.4  ||| S:2034 E:2039 ||| CD
weeks ||| S:2039 E:2044 ||| NNS
) ||| S:2044 E:2045 ||| -RRB-
.  ||| S:2045 E:2047 ||| .
Patients  ||| S:2047 E:2056 ||| NNS
treated  ||| S:2056 E:2064 ||| VBN
with  ||| S:2064 E:2069 ||| IN
eltrombopag  ||| S:2069 E:2081 ||| VBG
required  ||| S:2081 E:2090 ||| VBN
less  ||| S:2090 E:2095 ||| JJR
rescue  ||| S:2095 E:2102 ||| NN
medication  ||| S:2102 E:2113 ||| NN
and  ||| S:2113 E:2117 ||| CC
had  ||| S:2117 E:2121 ||| VBD
lower  ||| S:2121 E:2127 ||| JJR
odds  ||| S:2127 E:2132 ||| NNS
of  ||| S:2132 E:2135 ||| IN
bleeding  ||| S:2135 E:2144 ||| VBG
events  ||| S:2144 E:2151 ||| NNS
than  ||| S:2151 E:2156 ||| IN
placebo-treated  ||| S:2156 E:2172 ||| JJ
subjects  ||| S:2172 E:2181 ||| NNS
in  ||| S:2181 E:2184 ||| IN
both  ||| S:2184 E:2189 ||| DT
patient  ||| S:2189 E:2197 ||| JJ
groups ||| S:2197 E:2203 ||| NNS
.  ||| S:2203 E:2205 ||| .
In  ||| S:2205 E:2208 ||| IN
the  ||| S:2208 E:2212 ||| DT
watch-and-rescue  ||| S:2212 E:2229 ||| JJ
economic  ||| S:2229 E:2238 ||| JJ
model ||| S:2238 E:2243 ||| NN
,  ||| S:2243 E:2245 ||| ,
the  ||| S:2245 E:2249 ||| DT
ERG  ||| S:2249 E:2253 ||| NNP
found  ||| S:2253 E:2259 ||| VBD
that  ||| S:2259 E:2264 ||| DT
substantial  ||| S:2264 E:2276 ||| JJ
reductions  ||| S:2276 E:2287 ||| NNS
in  ||| S:2287 E:2290 ||| IN
the  ||| S:2290 E:2294 ||| DT
cost  ||| S:2294 E:2299 ||| NN
of  ||| S:2299 E:2302 ||| IN
eltrombopag  ||| S:2302 E:2314 ||| NNS
are  ||| S:2314 E:2318 ||| VBP
needed  ||| S:2318 E:2325 ||| VBN
for  ||| S:2325 E:2329 ||| IN
the  ||| S:2329 E:2333 ||| DT
incremental  ||| S:2333 E:2345 ||| JJ
cost-effectiveness  ||| S:2345 E:2364 ||| JJ
ratio  ||| S:2364 E:2370 ||| NN
( ||| S:2370 E:2371 ||| -LRB-
ICER ||| S:2371 E:2375 ||| NNP
)  ||| S:2375 E:2377 ||| -RRB-
to  ||| S:2377 E:2380 ||| TO
fall  ||| S:2380 E:2385 ||| VB
below  ||| S:2385 E:2391 ||| IN
Â£  ||| S:2391 E:2393 ||| CD
30,000 ||| S:2393 E:2399 ||| CD
.  ||| S:2399 E:2401 ||| .
Further  ||| S:2401 E:2409 ||| JJ
analyses  ||| S:2409 E:2418 ||| NNS
found  ||| S:2418 E:2424 ||| VBD
that  ||| S:2424 E:2429 ||| IN
the  ||| S:2429 E:2433 ||| DT
ICER  ||| S:2433 E:2438 ||| NNP
varied  ||| S:2438 E:2445 ||| VBD
from  ||| S:2445 E:2450 ||| IN
Â£33,561  ||| S:2450 E:2458 ||| CD
to  ||| S:2458 E:2461 ||| TO
Â£  ||| S:2461 E:2463 ||| FW
103,500  ||| S:2463 E:2471 ||| FW
per  ||| S:2471 E:2475 ||| FW
quality-adjusted  ||| S:2475 E:2492 ||| FW
life-year  ||| S:2492 E:2502 ||| FW
( ||| S:2502 E:2503 ||| -LRB-
QALY ||| S:2503 E:2507 ||| NNP
)  ||| S:2507 E:2509 ||| -RRB-
( ||| S:2509 E:2510 ||| -LRB-
splenectomised ||| S:2510 E:2524 ||| LS
)  ||| S:2524 E:2526 ||| -RRB-
and  ||| S:2526 E:2530 ||| CC
from  ||| S:2530 E:2535 ||| IN
Â£  ||| S:2535 E:2537 ||| CD
39,657  ||| S:2537 E:2544 ||| CD
to  ||| S:2544 E:2547 ||| TO
Â£  ||| S:2547 E:2549 ||| CD
150,245  ||| S:2549 E:2557 ||| CD
per  ||| S:2557 E:2561 ||| IN
QALY  ||| S:2561 E:2566 ||| NNP
( ||| S:2566 E:2567 ||| -LRB-
non-splenectomised ||| S:2567 E:2585 ||| NNP
) ||| S:2585 E:2586 ||| -RRB-
.  ||| S:2586 E:2588 ||| .
Other  ||| S:2588 E:2594 ||| JJ
than  ||| S:2594 E:2599 ||| IN
bleeding ||| S:2599 E:2607 ||| NN
,  ||| S:2607 E:2609 ||| ,
no  ||| S:2609 E:2612 ||| DT
adverse  ||| S:2612 E:2620 ||| JJ
events  ||| S:2620 E:2627 ||| NNS
were  ||| S:2627 E:2632 ||| VBD
modelled ||| S:2632 E:2640 ||| VBN
.  ||| S:2640 E:2642 ||| .
In  ||| S:2642 E:2645 ||| IN
relation  ||| S:2645 E:2654 ||| NN
to  ||| S:2654 E:2657 ||| TO
the  ||| S:2657 E:2661 ||| DT
long-term  ||| S:2661 E:2671 ||| JJ
treatment  ||| S:2671 E:2681 ||| NN
model ||| S:2681 E:2686 ||| NN
,  ||| S:2686 E:2688 ||| ,
the  ||| S:2688 E:2692 ||| DT
ERG  ||| S:2692 E:2696 ||| NNP
found  ||| S:2696 E:2702 ||| VBD
that  ||| S:2702 E:2707 ||| IN
using  ||| S:2707 E:2713 ||| VBG
non-randomised  ||| S:2713 E:2728 ||| JJ
non-comparative  ||| S:2728 E:2744 ||| JJ
data  ||| S:2744 E:2749 ||| NNS
may  ||| S:2749 E:2753 ||| MD
result  ||| S:2753 E:2760 ||| VB
in  ||| S:2760 E:2763 ||| IN
biased  ||| S:2763 E:2770 ||| JJ
estimates  ||| S:2770 E:2780 ||| NNS
of  ||| S:2780 E:2783 ||| IN
unknown  ||| S:2783 E:2791 ||| JJ
magnitude  ||| S:2791 E:2801 ||| NN
and  ||| S:2801 E:2805 ||| CC
direction ||| S:2805 E:2814 ||| NN
.  ||| S:2814 E:2816 ||| .
None  ||| S:2816 E:2821 ||| NN
of  ||| S:2821 E:2824 ||| IN
the  ||| S:2824 E:2828 ||| DT
treatment  ||| S:2828 E:2838 ||| NN
sequences  ||| S:2838 E:2848 ||| VBZ
resulted  ||| S:2848 E:2857 ||| VBN
in  ||| S:2857 E:2860 ||| IN
an  ||| S:2860 E:2863 ||| DT
ICER  ||| S:2863 E:2868 ||| NNP
approaching  ||| S:2868 E:2880 ||| VBG
the  ||| S:2880 E:2884 ||| DT
recommended  ||| S:2884 E:2896 ||| JJ
threshold  ||| S:2896 E:2906 ||| NN
of  ||| S:2906 E:2909 ||| IN
Â£  ||| S:2909 E:2911 ||| CD
30,000 ||| S:2911 E:2917 ||| CD
.  ||| S:2917 E:2919 ||| .
The  ||| S:2919 E:2923 ||| DT
base-case  ||| S:2923 E:2933 ||| JJ
results ||| S:2933 E:2940 ||| NNS
,  ||| S:2940 E:2942 ||| ,
using  ||| S:2942 E:2948 ||| VBG
a  ||| S:2948 E:2950 ||| DT
2-year  ||| S:2950 E:2957 ||| JJ
time  ||| S:2957 E:2962 ||| NN
horizon  ||| S:2962 E:2970 ||| NN
and  ||| S:2970 E:2974 ||| CC
prescribing  ||| S:2974 E:2986 ||| JJ
eltrombopag  ||| S:2986 E:2998 ||| NN
as  ||| S:2998 E:3001 ||| IN
second-line  ||| S:3001 E:3013 ||| JJ
treatment  ||| S:3013 E:3023 ||| NN
post  ||| S:3023 E:3028 ||| NN
rituximab ||| S:3028 E:3037 ||| NN
,  ||| S:3037 E:3039 ||| ,
were  ||| S:3039 E:3044 ||| VBD
found  ||| S:3044 E:3050 ||| VBN
to  ||| S:3050 E:3053 ||| TO
be  ||| S:3053 E:3056 ||| VB
favourable  ||| S:3056 E:3067 ||| VBN
towards  ||| S:3067 E:3075 ||| IN
eltrombopag ||| S:3075 E:3086 ||| NN
.  ||| S:3086 E:3088 ||| .
In  ||| S:3088 E:3091 ||| IN
conclusion ||| S:3091 E:3101 ||| NN
,  ||| S:3101 E:3103 ||| ,
based  ||| S:3103 E:3109 ||| VBN
on  ||| S:3109 E:3112 ||| IN
the  ||| S:3112 E:3116 ||| DT
MS  ||| S:3116 E:3119 ||| NNP
and  ||| S:3119 E:3123 ||| CC
additional  ||| S:3123 E:3134 ||| JJ
ERG  ||| S:3134 E:3138 ||| NNP
work ||| S:3138 E:3142 ||| NN
,  ||| S:3142 E:3144 ||| ,
eltrombopag  ||| S:3144 E:3156 ||| NN
appears  ||| S:3156 E:3164 ||| VBZ
to  ||| S:3164 E:3167 ||| TO
be  ||| S:3167 E:3170 ||| VB
a  ||| S:3170 E:3172 ||| DT
safe  ||| S:3172 E:3177 ||| JJ
treatment  ||| S:3177 E:3187 ||| NN
for  ||| S:3187 E:3191 ||| IN
ITP  ||| S:3191 E:3195 ||| NNP
( ||| S:3195 E:3196 ||| -LRB-
although  ||| S:3196 E:3205 ||| IN
long-term  ||| S:3205 E:3215 ||| JJ
follow-up  ||| S:3215 E:3225 ||| JJ
studies  ||| S:3225 E:3233 ||| NNS
are  ||| S:3233 E:3237 ||| VBP
awaited ||| S:3237 E:3244 ||| VBN
)  ||| S:3244 E:3246 ||| -RRB-
and  ||| S:3246 E:3250 ||| CC
has  ||| S:3250 E:3254 ||| VBZ
short-term  ||| S:3254 E:3265 ||| JJ
efficacy ||| S:3265 E:3273 ||| NN
.  ||| S:3273 E:3275 ||| .
However ||| S:3275 E:3282 ||| RB
,  ||| S:3282 E:3284 ||| ,
there  ||| S:3284 E:3290 ||| EX
is  ||| S:3290 E:3293 ||| VBZ
no  ||| S:3293 E:3296 ||| DT
robust  ||| S:3296 E:3303 ||| JJ
evidence  ||| S:3303 E:3312 ||| NN
on  ||| S:3312 E:3315 ||| IN
long-term  ||| S:3315 E:3325 ||| JJ
efficacy  ||| S:3325 E:3334 ||| NN
or  ||| S:3334 E:3337 ||| CC
cost-effectiveness  ||| S:3337 E:3356 ||| JJ
of  ||| S:3356 E:3359 ||| IN
eltrombopag ||| S:3359 E:3370 ||| NN
,  ||| S:3370 E:3372 ||| ,
and  ||| S:3372 E:3376 ||| CC
there  ||| S:3376 E:3382 ||| EX
is  ||| S:3382 E:3385 ||| VBZ
a  ||| S:3385 E:3387 ||| DT
lack  ||| S:3387 E:3392 ||| NN
of  ||| S:3392 E:3395 ||| IN
robust  ||| S:3395 E:3402 ||| JJ
direct  ||| S:3402 E:3409 ||| JJ
evidence  ||| S:3409 E:3418 ||| NN
on  ||| S:3418 E:3421 ||| IN
the  ||| S:3421 E:3425 ||| DT
effectiveness  ||| S:3425 E:3439 ||| NN
and  ||| S:3439 E:3443 ||| CC
cost-effectiveness  ||| S:3443 E:3462 ||| JJ
of  ||| S:3462 E:3465 ||| IN
eltrombopag  ||| S:3465 E:3477 ||| VBG
compared  ||| S:3477 E:3486 ||| VBN
with  ||| S:3486 E:3491 ||| IN
other  ||| S:3491 E:3497 ||| JJ
relevant  ||| S:3497 E:3506 ||| JJ
comparators ||| S:3506 E:3517 ||| NN
.  ||| S:3517 E:3519 ||| .
NICE  ||| S:3519 E:3524 ||| JJ
did  ||| S:3524 E:3528 ||| VBD
not  ||| S:3528 E:3532 ||| RB
recommend  ||| S:3532 E:3542 ||| VB
eltrombopag  ||| S:3542 E:3554 ||| VBN
for  ||| S:3554 E:3558 ||| IN
the  ||| S:3558 E:3562 ||| DT
treatment  ||| S:3562 E:3572 ||| NN
of  ||| S:3572 E:3575 ||| IN
chronic  ||| S:3575 E:3583 ||| JJ
ITP  ||| S:3583 E:3587 ||| NN
within  ||| S:3587 E:3594 ||| IN
its  ||| S:3594 E:3598 ||| PRP$
marketing  ||| S:3598 E:3608 ||| NN
authorisation  ||| S:3608 E:3622 ||| NN
for  ||| S:3622 E:3626 ||| IN
splenectomised  ||| S:3626 E:3641 ||| NN
or  ||| S:3641 E:3644 ||| CC
non-splenectomised  ||| S:3644 E:3663 ||| JJ
patients ||| S:3663 E:3671 ||| NNS
.  ||| S:3671 E:3673 ||| .
